Malignant tumor
Conditions
Interventions
Exposed group:None
Non-exposed group:None
Sponsors
Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years old; 2. ECOG PS 0 or 1; 3. Patients with malignant tumors; 4. Already diagnosed with coronary atherosclerotic heart disease, and assessed as high-risk or above by the overall ASCVD risk assessment; 5. Able to comply with the protocol during the study period; 6. Provided written informed consent before entering the study, and the patient has understood that they can withdraw from the study at any time without any loss.
Exclusion criteria
Exclusion criteria: 1.Patients with severe heart, liver, kidney, lung and other important organ insufficiency; 2.Allergy to iodine or contrast media; 3.Severe water and electrolyte disorders; 4.Presence of coagulopathy; 5.Those who have gastrointestinal bleeding within two weeks prior to enrollment, or who are judged by the investigator to have a high risk of bleeding; 6.Presence of an underlying medical condition that, in the opinion of the investigator, is not conducive to the study; 7.Patients who have had an allogeneic stem cell transplant or organ transplant; 8.Patients treated with ICIs;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in plaque properties; | — |
Secondary
| Measure | Time frame |
|---|---|
| Major Adverse Cardiovascular Events;Plaque volume changes;Changes in LDL-C levels;Change in calcification integral;Change in plaque loading; | — |
Countries
China
Contacts
Public ContactYao Zhifeng
Zhongshan Hospital, Fudan University
Outcome results
None listed